Journal Article

DZNE-2025-00937

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png Machine learning applications in vascular neuroimaging for the diagnosis and prognosis of cognitive impairment and dementia: a systematic review and meta-analysis.

Lohner, V. ; Badhwar, A. ; Detcheverry, F. E. ; García, C. L. ; Gellersen, H. M.DZNE* ; Khodakarami, Z. ; Lattmann, R.DZNE* ; Li, R. ; Low, A. ; Mazo, C. ; Metz, A. ; Parent, O. ; Phillips, V. ; Saeed, U. ; Tan, S. Y. W. ; Tamburin, S. ; Llewellyn, D. J. ; Rittman, T. ; Waters, S. ; Bernal, J. (Last author)DZNE*

2025
BioMed Central London

This record in other databases:    

Please use a persistent id in citations: doi:10.1186/s13195-025-01815-6

Abstract: Background:Cerebral small vessel disease (CSVD) is a common neurological condition that contributes to strokes, dementia, disability, and mortality worldwide. We conducted a systematic review and meta-analysis to investigate the use of neuroimaging CSVD markers in machine learning (ML) based diagnosis and prognosis of cognitive impairment and dementia, and identify both methodological changes over time and barriers to clinical translation.Methods:Following the PRISMA guidelines, we systematically searched for original studies that used both neuroimaging CSVD markers and ML methods for diagnosing and prognosing neurodegenerative diseases (preregistration in PROSPERO: CRD42022366767). Each paper was independently reviewed by a pair of reviewers at all stages, with a third consulted to resolve conflicts. We meta-analysed the effectiveness of ML models to distinguish healthy controls from Alzheimer’s dementia and cognitive impairment, using area under the curve (AUC) as the performance metric.Results:We identified 75 studies: 43 on diagnosis, 27 on prognosis, and 5 on both. Nearly 60% of studies were published in the past two years, reflecting a growing interest in using CSVD markers in ML-based diagnosis and prognosis of neurodegenerative diseases, especially Alzheimer’s dementia. This rising interest may be linked to the strong performance of such models: according to our meta-analysis, ML approaches using CSVD markers perform well in differentiating healthy controls from Alzheimer’s dementia (AUC 0.88 [95%-CI 0.85–0.92]) and cognitive impairment (AUC 0.84 [95%-CI 0.74–0.95]). However, the growing interest has not been matched by methodological rigour: only 16 studies met the criteria for inclusion in the meta-analysis due to inconsistent reporting, only five assessed the generalisability of their models on external datasets, and six lacked clear diagnostic criteria.Conclusions:Interest in incorporating CSVD markers into ML models for neurodegenerative disease classification is on the rise, and their performance suggests that this is worth further exploration. Serious methodological issues, including inconsistent reporting, limited generalisability testing, and other potential biases, are unfortunately common and hinder further adoption. Our targeted recommendations provide a roadmap to accelerate the integration of ML into clinical practice.

Keyword(s): Alzheimer’s dementia ; Artificial intelligence ; Cerebral small vessel disease ; Cognitive impairment ; Dementia ; Machine learning ; Neurodegenerative diseases ; Neuroimaging

---

Contributing Institute(s):

1. Clinical Cognitive Neuroscience (AG Berron)
2. Clinical Neurophysiology and Memory (AG Düzel)

Research Program(s):

1. 353 - Clinical and Health Care Research (POF4-353) (POF4-353)

Appears in the scientific report 2025

---

Database coverage:
; ; ; ; Article Processing Charges ; Clarivate Analytics Master Journal List ; Current Contents - Clinical Medicine ; DOAJ Seal ; Ebsco Academic Search ; Essential Science Indicators ; Fees ; IF >= 5 ; JCR ; SCOPUS ; Science Citation Index Expanded ; Web of Science Core Collection

---